ClinicalTrials.Veeva

Menu

Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma. (SCLERO-PID)

U

University Hospital, Lille

Status

Completed

Conditions

Systemic Sclerosis

Treatments

Other: lung function tests

Study type

Observational

Funder types

Other

Identifiers

NCT03271333
2016-A00722-49 (Other Identifier)
2015_49

Details and patient eligibility

About

Diffuse infiltrating pneumonia (DIP) is a severe complication of systemic sclerosis and one of the leading cause of death in this condition. The main objective of this study is to prospectively describe the evolution of DIP overtime and to find prognosis factors.

Enrollment

56 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • systemic sclerosis
  • Diffuse Infiltrating Pneumonia

Exclusion criteria

  • infection
  • other lung diseases
  • non French native

Trial design

56 participants in 1 patient group

patients with systemic sclerosis
Treatment:
Other: lung function tests

Trial contacts and locations

2

Loading...

Central trial contact

David Launay, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems